Skip to main content
NewslettersWatchlist

Cns Pharmaceuticals Inc(CNSP-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.2007
Day High0.2200
Open:0.2100
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event
Investor Brand Network
CNS Pharmaceuticals’ (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Board
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering Pricing
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification
Investor Brand Network
CNS Pharmaceuticals’ (NASDAQ: CNSP) Interim Analysis on Berubicin Trial Showing Promising Results
ACCESSWIRE
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study
ACCESSWIRE
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Releases Q3 2023 Results, Update on Berubicin Study
ACCESSWIRE
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
ACCESSWIRE
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate at Virtual Investor Ask the CEO Conference
ACCESSWIRE
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
Investor Brand Network
CNS Pharmaceuticals’ (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’
ACCESSWIRE
Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals’ Innovative Approach To Treatment Could Offer Hope
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Berubicin Study
ACCESSWIRE
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Optimistic Berubicin May Provide Benefit for GBM Patients
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Looking Forward to Interim Results for Potentially Pivotal GBM Study
ACCESSWIRE
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate at H.C. Wainwright Global Investment Conference
ACCESSWIRE
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Announces Q2 2023 Results
ACCESSWIRE
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

Profile

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is based in Houston, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.